[
  {
    "ts": "2025-11-07T13:34:16+00:00",
    "headline": "Gilead Sciences Says Long-Term Data Supports Sustained Efficacy, Safety of Primary Biliary Cholangitis Drug",
    "summary": "Gilead Sciences (GILD) said Friday that new long-term data on its drug Livdelzi showed consistent ef",
    "url": "https://finance.yahoo.com/news/gilead-sciences-says-long-term-133416316.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "aad950f5-1f14-349a-b994-db18f51a5b48",
      "content": {
        "id": "aad950f5-1f14-349a-b994-db18f51a5b48",
        "contentType": "STORY",
        "title": "Gilead Sciences Says Long-Term Data Supports Sustained Efficacy, Safety of Primary Biliary Cholangitis Drug",
        "description": "",
        "summary": "Gilead Sciences (GILD) said Friday that new long-term data on its drug Livdelzi showed consistent ef",
        "pubDate": "2025-11-07T13:34:16Z",
        "displayTime": "2025-11-07T13:34:16Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-says-long-term-133416316.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-sciences-says-long-term-133416316.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T13:30:00+00:00",
    "headline": "Gilead Provides Update on Phase 3 ASCENT-07 Study",
    "summary": "FOSTER CITY, Calif., November 07, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the Phase 3 ASCENT-07 study investigating Trodelvy® (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer patients did not meet the primary endpoint of progression-free survival (PFS) as assessed by Blinded Independent Central Review (BICR) according to RECIST v1.1 criteria.",
    "url": "https://finance.yahoo.com/news/gilead-provides-phase-3-ascent-133000120.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "c1e4a9de-ca31-330a-82e9-8c09b8920039",
      "content": {
        "id": "c1e4a9de-ca31-330a-82e9-8c09b8920039",
        "contentType": "STORY",
        "title": "Gilead Provides Update on Phase 3 ASCENT-07 Study",
        "description": "",
        "summary": "FOSTER CITY, Calif., November 07, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the Phase 3 ASCENT-07 study investigating Trodelvy® (sacituzumab govitecan-hziy) versus chemotherapy as a first-line treatment post-endocrine therapy in HR+/HER2-negative metastatic breast cancer patients did not meet the primary endpoint of progression-free survival (PFS) as assessed by Blinded Independent Central Review (BICR) according to RECIST v1.1 criteria.",
        "pubDate": "2025-11-07T13:30:00Z",
        "displayTime": "2025-11-07T13:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/82a775dccb85151be8434b7cb8f43caa",
          "originalWidth": 1728,
          "originalHeight": 576,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7q6XARwW.2RAILrSat7pCg--~B/aD01NzY7dz0xNzI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/82a775dccb85151be8434b7cb8f43caa.cf.webp",
              "width": 1728,
              "height": 576,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/z6Dh9R62OXVyIUEZW_kqAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/82a775dccb85151be8434b7cb8f43caa.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-provides-phase-3-ascent-133000120.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-provides-phase-3-ascent-133000120.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T13:00:00+00:00",
    "headline": "Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression",
    "summary": "FOSTER CITY, Calif., November 07, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new long-term data reinforcing the safety and efficacy profile of Livdelzi® (seladelpar) for people living with primary biliary cholangitis (PBC). Findings support Livdelzi's consistent efficacy and safety outcomes in patients switching from obeticholic acid and positive impact on liver stiffness over 3 years. These findings were presented at The Liver Meeting® hosted by the American Association for the",
    "url": "https://finance.yahoo.com/news/gilead-livdelzi-demonstrates-sustained-efficacy-130000398.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "55e86795-7ae4-3abe-89b5-8e547d9dae92",
      "content": {
        "id": "55e86795-7ae4-3abe-89b5-8e547d9dae92",
        "contentType": "STORY",
        "title": "Gilead’s Livdelzi® Demonstrates Sustained Efficacy in Primary Biliary Cholangitis (PBC), Offering Alkaline Phosphatase (ALP) Reduction, Itch Relief and Potential to Slow Disease Progression",
        "description": "",
        "summary": "FOSTER CITY, Calif., November 07, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new long-term data reinforcing the safety and efficacy profile of Livdelzi® (seladelpar) for people living with primary biliary cholangitis (PBC). Findings support Livdelzi's consistent efficacy and safety outcomes in patients switching from obeticholic acid and positive impact on liver stiffness over 3 years. These findings were presented at The Liver Meeting® hosted by the American Association for the",
        "pubDate": "2025-11-07T13:00:00Z",
        "displayTime": "2025-11-07T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/dce23046492b03377f1893b11226341e",
          "originalWidth": 1728,
          "originalHeight": 576,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/AdDY2e3gsvmVygkUNNTCXw--~B/aD01NzY7dz0xNzI4O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/dce23046492b03377f1893b11226341e.cf.webp",
              "width": 1728,
              "height": 576,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DWN2PQ7k_uMLA.2ovR.NOg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/dce23046492b03377f1893b11226341e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/gilead-livdelzi-demonstrates-sustained-efficacy-130000398.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/gilead-livdelzi-demonstrates-sustained-efficacy-130000398.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T19:01:27+00:00",
    "headline": "Sector Update: Health Care Stocks Retreat Friday Afternoon",
    "summary": "Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the Health Care Se",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-retreat-190127848.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "4c121cfc-407f-3c7e-aff5-ea3828ef9d4f",
      "content": {
        "id": "4c121cfc-407f-3c7e-aff5-ea3828ef9d4f",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Retreat Friday Afternoon",
        "description": "",
        "summary": "Health care stocks declined Friday afternoon, with the NYSE Health Care Index and the Health Care Se",
        "pubDate": "2025-11-07T19:01:27Z",
        "displayTime": "2025-11-07T19:01:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-retreat-190127848.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-retreat-190127848.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "RYTM"
            },
            {
              "symbol": "XLV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-07T21:01:45+00:00",
    "headline": "Sector Update: Health Care Stocks Ease Late Afternoon",
    "summary": "Health care stocks edged lower late Friday afternoon, with the NYSE Health Care Index shedding 0.1%",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-ease-210145974.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "4e055593-a905-30bc-8ae3-401081e751c4",
      "content": {
        "id": "4e055593-a905-30bc-8ae3-401081e751c4",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Ease Late Afternoon",
        "description": "",
        "summary": "Health care stocks edged lower late Friday afternoon, with the NYSE Health Care Index shedding 0.1%",
        "pubDate": "2025-11-07T21:01:45Z",
        "displayTime": "2025-11-07T21:01:45Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-ease-210145974.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-ease-210145974.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "GILD"
            },
            {
              "symbol": "MRNA"
            },
            {
              "symbol": "GMED"
            },
            {
              "symbol": "XLV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]